Pfizer Announces Top Results of ABRYSVO for RSV in Immunocompromised Adults

Pfizer Inc. (NYSE: PFE) today announced positive topline safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONET money (HSV IMmunizatiON Study for adultsTs at higher risk of severe disease), evaluating two doses of ABRYSVO vaccine in immunocompromised adults 18 years of age and older who are at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD).

Adults with immunocompromised conditions are at increased risk of developing RSV-LRTD. Substudy B of the MONeT trial was conducted to evaluate the safety and immunogenicity of two doses of ABRYSVO administered one month apart in four groups of immunocompromised adults: those with non-small cell lung cancer, those undergoing hemodialysis for end-stage renal disease, those with an autoimmune inflammatory disease receiving active immunomodulator therapy, and solid organ transplant recipients. Of the 203 adults enrolled in the substudy, approximately half were between the ages of 18 and 59 and approximately half were 60 years of age or older.